Glycopyrronium
Antihidrotics
Sold as TRIMBOW · Bevespi Aerosphere · Riltrava Aerosphere · SEEBRI BREEZHALER
- Drug class
- Antihidrotics
- Availability
- See label
- Routes
- Inhalation
- Markets covered
- 3
- Products on record
- 20
Overview
Glycopyrronium is an active pharmaceutical ingredient in the Antihidrotics group (D11AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 14 | May 1, 2026 |
| CA Canada | Health Canada | 4 | January 7, 2026 |
| EU European Union | EMA | 2 | September 30, 2025 |
GBUnited Kingdom· MHRA
14 products
Uses
Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.
How to take
CACanada· Health Canada
4 products
Uses
APO-GLYCOPYRRONIUM (glycopyrronium bromide) is indicated as a long-term once-daily maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. APO-GLYCOPYRRONIUM is not indicated for the relief of an acute deterioration of COPD.
1 Pediatrics Pediatrics (< 18 years of age): APO-GLYCOPYRRONIUM should not be used in patients under 18 years of age. 2 Geriatrics Geriatrics (> 65 years of age): APO-GLYCOPYRRONIUM can be used at the recommended dose in elderly patients 65 years of age and older.
How to take
EUEuropean Union· EMA
2 products
Uses
1).
How to take
Drug interactions
Known interactions involving Glycopyrronium. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL064643139 · revised March 20, 2026
- [2]Health Canada (DPD) · 02563657 · revised January 7, 2026
- [3]European Medicines Agency · EMEA/H/C/005311 · revised September 30, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.